Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has disclosed that it has received authorization from the European Commission to start the treatment of patients ages six years and older suffering from cystic fibrosis. The patients will get the treatment with SYMKEVI in combination with KALYDECO. This